Cadila Clarifies Voluntary Recall Of Drugs In The US Market
Advertisement
Advertisement
Advertisement
Drug maker "The recall by our US subsidiary was voluntary and a class-III type recall, which means that the use of the product is not likely to cause any adverse health consequences. There is no material impact”, said the company in a letter to the National Stock Exchange (
The NSE on December 31, 2014, had sought clarification from the pharma major after a news report suggested that along with Wockhardt and Hospira, Cadila too has voluntarily recalled 58,920 bottles of Benzonatate Capsules—these medicines are used to treat coughs. The US Food and Drug Administration (
Representational Image
Advertisement
- Should you be worried about the potential side-effects of the Covishield vaccine?
- India T20 World Cup squad: KulCha back on menu, KL Rahul dropped
- Sales of homes priced over ₹4 crore rise 10% in Jan-Mar in top 7 cities: CBRE
- Gold prices fluctuate as geopolitical tensions ease; US Fed meeting, payroll data to affect prices this week
- Best beaches to visit in Goa in 2024
- Nothing Phone (2a) blue edition launched
- JNK India IPO allotment date
- JioCinema New Plans
- Realme Narzo 70 Launched
- Apple Let Loose event
- Elon Musk Apology
- RIL cash flows
- Charlie Munger
- Feedbank IPO allotment
- Tata IPO allotment
- Most generous retirement plans
- Broadcom lays off
- Cibil Score vs Cibil Report
- Birla and Bajaj in top Richest
- Nestle Sept 2023 report
- India Equity Market